跳至主要内容
临床试验/NCT03292575
NCT03292575已完成不适用

Prevention of Cardio-embolic Stroke Using Anti-vitamin K and Direct Oral Anticoagulants. A Model of Action in Burgundy.

Centre Hospitalier Universitaire Dijon1 个研究点 分布在 1 个国家目标入组 441 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
441
试验地点
1
主要终点
rate of stroke recurrences

研究概览

简要总结

Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap). Ischemic cardio-embolic stroke accounts for around 25% of ischemic strokes, and ischemic cardio-embolic stroke in a context of cardiac arrhythmia due to atrial fibrillation (CAAF) is the leading non-atheromatous cause. The aim of this study is to optimise the secondary prevention of CAAF-related stroke identified at the University Hospital of Dijon Burgundy in the framework of the recommendations of the '2010-2014 stroke plan' and the Compulsory Consultation at the 6th month (Directive DGOS//2015/262 of the 3rd August 2015)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients managed for stroke at the stroke unit of Dijon University Hospital for CAAF-related cardio-embolic stroke

排除标准

  • 未提供

研究组 & 干预措施

Stroke related to CAAF

干预措施: Anticoagulants (Drug)

结局指标

主要结局

rate of stroke recurrences

时间窗: 12 months after inclusion

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study of the Follow-up of Stroke Treated With... | 临床试验